BioForm Medical, Inc. 

(Public, NASDAQ:BFRM)   Watch this stock   
Find more results for BFRM
Nov 4, 2009
BIOFORM MEDICAL INC at Oppenheimer & Co. Healthcare Conference
Nov 2, 2009
Q1 2010 BIOFORM MEDICAL INC Earnings Release
Nov 2, 2009
Q1 2010 BIOFORM MEDICAL INC Earnings Conference Call
Sep 29, 2009
BIOFORM MEDICAL INC at Maxim Group Conference
More events from AOL Finance »    

Key stats and ratios

Q2 (Jun '09) 2009
Net profit margin -9.79% -31.75%
Operating margin -9.80% -31.37%
EBITD margin - -28.46%
Return on average assets -10.40% -25.41%
Return on average equity -11.74% -28.98%
Employees 310 -

Address

1875 South Grant Street Suite 200
San Mateo, CA 94402
United States - Map
+1-650-2864000 (Phone)
+1-650-2864090 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

BioForm Medical, Inc. discussed on blogs

Ranking 1100+ Micro Cap Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 20, 2009

BioForm Medical, Inc. discussions

  View all discussions »

Description

BioForm Medical, Inc. (BioForm) is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient’s appearance. The Company’s product is RADIESSE, an injectable dermal filler designed to provide aesthetic improvement for patients. RADIESSE provides initial aesthetic correction and approximately 12 months’ duration of aesthetic improvement in many patients. The Company has shipped over 1,000,000 syringes worldwide. It has obtained licenses to or acquired three products: Polidocanol, a sclerotherapy treatment in Europe for varicose veins sold under the trade name Aethoxysklerol; BIOGLUE AESTHETIC medical adhesive, a Class III medical device in clinical testing for tissue fixation in browplasty, or forehead lift, and RELAXED EXPRESSIONS System, a radiofrequency 510(k) medical device cleared by the United States Food and Drug Administration (FDA), for use in creating radiofrequency (RF) heat lesions in nerve tissue.

Officers and directors

Steven L. Basta
Chief Executive Officer, Director
Age: 44
Bio & Compensation - Reuters
Dennis E. Condon
President, Chief Business Officer, Director
Age: 60
Bio & Compensation - Reuters
Frederick Lwee
Principal Financial Officer, Vice President - Finance, Controller, Assistant Secretary
Age: 28
Bio & Compensation - Reuters
Adam Gridley
Senior Vice President - Corporate Development
Age: 37
Bio & Compensation - Reuters
Martin P. Sutter
Lead Director
Age: 54
Bio & Compensation - Reuters
Timothy P. Lynch
Director
Age: 39
Bio & Compensation - Reuters
Kevin Sidow
Director
Bio & Compensation - Reuters
N.C. Joseph Lai Ph.D.
Director
Bio & Compensation - Reuters
Christopher John Wesley Dennis
Director
Age: 50
Bio & Compensation - Reuters